Capricor Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (28)

Latest Posts

About This Stock More About This Stock
E Blockbuster SAR-CoV2 Disrupters Pre-ICU / Admitted ICU Patient Treatments & COVID-19 T-Cell Vaccine Horizon
Article By: James Gornick
Wednesday, July 22, 2020 5:50 AM EDT
In recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating, or preventing COVID-19.
In this article: CAPR, ATHX Also: BMRN, AZN, PFE, INO, NVAX, REGN, XLY, MRNA, BNTX, SRNE
Read
E Capricor Therapeutics Tumbles 60% On Failed Heart Attack Trial
Article By: Terry Chrisomalis
Friday, May 12, 2017 12:15 PM EDT
Capricor Therapeutics reported an update on its phase 2 trial known as Allstar. It stated that the drug, CAP-1002 showed a low probability of achieving the primary endpoint of the study.
In this article: CAPR
Read
Biotech Digest – JAZZ Reports Positive Results, CTSO Inks New Contract, AMGN Forges Collaboration
Article By: KKD Healthcare Analytics
Tuesday, April 25, 2017 10:15 AM EDT
Capricor Therapeutics announced encouraging six-month results in a Phase 1/2 clinical trial. Jazz Pharmaceuticals reported results from its Phase 2/3 clinical trial. Amgen announced its new collaboration with Novartis.
In this article: NVS, EAPH, ACHN, JAZZ, AMGN, CANF, CAPR, CTSO
Read

PARTNER HEADLINES

Latest Tweets for $CAPR

No tweets yet!